Key Statistics for UTHR
|Current P/E Ratio (ttm)
Relative P/E vs.
|Earnings Per Share (USD) (ttm)
|Est. EPS (USD) (12/2013)
|Est. PEG Ratio
|Market Cap (M USD)
|Shares Outstanding (M)
|30 Day Average Volume
|Dividend Indicated Gross Yield
|5 Year Dividend Growth
|Next Earnings Announcement
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for UTHR
- Net Income (M/USD)
United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.
More Company Profile & Key Executives for UTHR
|Martine A RothblattChairman/CEO/Founder||Roger A JeffsPresident/COO|
|John M FerrariCFO/Treasurer||Paul A MahonExec VP/Secy/General Counsel|
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.